Market research
ICCC ImmuCell Corporation
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 91M
- P/E ratio
- 143.71
- Analyst target
- 14
- Dividend yield
- Not available
- Beta
- 0.57
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US4525253062
- Market cap
- 91M
- P/E ratio
- 143.71
- Analyst target
- 14
- Dividend yield
- Not available
- Beta
- 0.57
About
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ICCC discussion.
5 years, 4 months ago
ImmuCell Corporation is currently in a long term uptrend where the price is trading 19.1% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.6.
ImmuCell Corporation's total revenue rose by 3.1% to $4M since the same quarter in the previous year.
Its net income has increased by 100.1% to $189 since the same quarter in the previous year.
Finally, its free cash flow grew by 82.6% to $-128K since the same quarter in the previous year.
Based on the above factors, ImmuCell Corporation gets an overall score of 5/5.